GlassScriptPhysician profile
Sean Vincent Lyons
NPI 1457307787
$662.29
in general payments reported to CMS, 2019-2025
14 companies · $79.38 in 2025
The $79.38 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $194 · 2020: $87.68 · 2021: $22.26 · 2023: $204 · 2024: $75.00 · 2025: $79.38.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $359.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $358.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| W. L. Gore & Associates, INC. | $135.94 | 2023 | Gore Viabahn Endoprosthesis With Heparin |
| Medtronic Vascular, INC. | $81.52 | 2019-2020 | |
| Medtronic, INC. | $79.38 | 2025 | Symplicity G3 |
| Novartis Pharmaceuticals Corporation | $71.74 | 2019-2023 | |
| Boston Scientific Corporation | $65.45 | 2023-2024 | |
| Pfizer INC. | $47.06 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $43.79 | 2019-2023 | Camzyos |
| Amgen INC. | $30.67 | 2019-2024 | Repatha |
| Chiesi USA, INC. | $25.56 | 2024 | Cleviprex |
| Amarin Pharma, INC. | $22.26 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $16.89 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.71 | 2019 | |
| Janssen Pharmaceuticals, INC | $13.87 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $12.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sean Lyons listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.